New CAPS pill enters first human tests
NCT ID NCT07247266
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing an experimental drug called JTE-162 in 5 adults with CAPS, a rare condition that causes fever, rash, and joint pain. Participants take one tablet daily for 2 weeks. Researchers will check if the drug safely reduces inflammation and improves symptoms. Because this is a very small, short study, it is mainly about safety and finding the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JTE-162 (an experimental drug taken as a tablet once daily)
- What this could lead to
- If it works, this could point toward a new daily treatment to control CAPS symptoms and reduce inflammation.
- What could go wrong
- This is a very early, tiny study (only 5 people) testing safety and short-term effects. It may not work or could have side effects. Much more research is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Gordon Sussman Clinical Research Inc.
RECRUITINGNorth York, Ontario, M3B 3S6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.